Angiogenesis

MET kinase-IN-3 is a potent, orally active MET inhibitor (IC50: 9.8 nM) that exhibits good broad-spectrum anti-proliferative effects on cancer cells.

KB SRC 4 is a selective and potent c-Src inhibitor with antitumour activity that inhibits the growth of cancer cells.CAS 번호13460-73-83-4

BPR1J-340, a novel potent FLT3 inhibitor, shows anticancer promise, with IC50 ~25 nM and GC50 ~5 nM, causing apoptosis in AML cells.

Risvodetinib: potent inhibitor of protein tyrosine kinases c-Abl1, c-Abl2, and c-kit.

DW10075, a novel potent and highly selective inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo.

BMX-IN-1 (BMX kinase inhibitor) is a selective inhibitor of bone marrow tyrosine kinase on chromosome X (BMX, IC50 = 8 nM) and the related Bruton’s tyrosine

HDAC-IN-50, a potent FGFR/HDAC inhibitor (IC50: 0.18-13 nM), induces apoptosis, cell cycle arrest, and shows anti-tumor activity.

DDa-1 is a potent (kinase degrader) [1].

<p>BGB-102 (JNJ-26483327) is a kinase inhibitor targeting FLT3 and YES1 and an antagonist targeting EGFR and VEGFR3.</p>

JND3229 inhibits EGFRC797S; IC50: 5.8-30.5 nM; halts cell growth; effective in non-small cell lung cancer study.

EVT801 is a highly selective and low-toxic VEGFR-3 inhibitor that inhibits VEGF-C-induced tumor lymphoid and angiogenesis and reduces CCL4, CCL5 and MDSC.

<p>TG 100572 Hydrochloride is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.</p>

15-deoxy-Δ12,14-Prostaglandin D2 (15-deoxy-Δ12,14-PGD2) is a PGD2 metabolite functioning as an agonist for the PGD2 receptor 2 (DP2), with a binding affinity (Ki) of 50 nM for the mouse DP2 receptor expressed in HEK293 cell membranes. It activates eosinophils with an EC50 of 8 nM and enhances the recruitment of steroid receptor coactivator-1 (SRC-1) to peroxisome proliferator-activated receptor γ (PPARγ), initiating PPARγ-mediated transcription at 5 µM concentration. Furthermore, it exhibits cytotoxicity towards L1210 murine leukemia cells with an IC50 of 0.3 µg/ml and displays weaker inhibition of ADP-induced platelet aggregation than PGD2, with an IC50 of 320 ng/ml.

(Rac)-PF-0625011 is a racemic mix, orally active, selective BTK inhibitor, also targeting BMX and TEC kinases.

ALK/ROS1-IN-1 is a potent and selective anti-crizotinib-resistant ALK/ROS1 dual inhibitor (IC50s: 0.530 μM and 0.174 μM for ROS1 and ALK enzyme).

EGFR mutant-in-1, a 5-methylpyrimidopyridone, selectively inhibits EGFRL858R/T790M/C797S mutants with an IC50 of 27.5 nM, lessening EGFRWT impact.

EGFR-IN-29 is a potent EGFR inhibitor.

JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.

OTS447 is a potent FLT3 inhibitor (IC50: 21 nM) with potential anticancer activity for cancer research .

<p>FM-479, a structural analog of FM-381, lacks inhibition of JAK3/kinases within 100-300 nM, serving as FM-381's negative control.</p>